Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors

BACKGROUND: Although checkpoint-based immunotherapy has shown exciting results in the treatment of tumors, around 70% of patients have experienced unresponsiveness. PVRIG is a recently identified immune checkpoint receptor and blockade of which could reverse T cell exhaustion to treat murine tumor;...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yangyang, Zhang, Yu, Cao, Guoshuai, Zheng, Xiaodong, Sun, Cheng, Wei, Haiming, Tian, Zhigang, Xiao, Weihua, Sun, Rui, Sun, Haoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236157/
https://www.ncbi.nlm.nih.gov/pubmed/34174928
http://dx.doi.org/10.1186/s13045-021-01112-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236157/
https://www.ncbi.nlm.nih.gov/pubmed/34174928
http://dx.doi.org/10.1186/s13045-021-01112-3

Ejemplares similares